dangers of glp 1 drugs GLP-1 and Eating Disorders: A Hidden Risk in the Weight Loss Revolution – The Chicago Council on Science and Technology glp 1 agonist risks Peptide/GLP-1

Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials

doi: 10.1007/s004419900093

of these, most of the candidates target metabolic disorders, such as Type 2 diabetes and obesity

NAION is the most common optic neuropathy in adults over 50, caused by hypoperfusion of short posterior ciliary arteries supplying the optic nerve, inducing swelling that creates compartment syndrome compressing neighboring axons, resulting in ganglion cell death

Furthermore, in this same cohort, there were no significant differences in the rates of hospitalization for HF between the treatment and placebo groups